Marinomed Biotech Reveals 2023 Financial Results & Progress with Marinosolv, Carragelose

• Revenues for 2023 financial year at EUR 9.2 million, a decrease from previous year
• Important progress made for Carragelose and Marinosolv assets
• Primary goal for 2024 and beyond is to achieve operating profitability through commercialization of assets
• Cash and cash equivalents decreased to EUR 2.6 million in 2023
• Operating result (EBIT) was EUR -5.1 million in 2023
• Outlook for 2024 includes growth in Carragelose business and concluding license deals for Budesolv and Tacrosolv

The next important date, Quarterly report, at Marinomed Biotech is on 20.05.2024.

The price of Marinomed Biotech at the time of the news was 19,675EUR and was down -0,13 % compared with the previous day.
14 minutes after the article was published, the price was 19,625EUR this corresponds to a minus of -0,25 % since publication.

Marinomed Biotech

-2,87 %

-11,73 %

-22,54 %

-41,84 %

-52,05 %

-86,93 %

-78,03 %

-77,46 %

ISIN:ATMARINOMED6WKN:A2N9MM

• Intraday
• 5 Tage
• 1 Monat
• 3M
• 1 Jahr
• 3J
• 5J
• Max